HOME >> Press release

Go East, Big Pharma
China Drug Firms Consolidate
Big Pharma, Flush With Cash, Is Looking Acquisitive
Tycoon ZhengYuewen Charts Water Private Hospital
Chinese Pharma Giants Slow Down Acquisition Steps
US Healthcare Organization Re-evaluate the Use of Vioxx
China Resources' Rough Road to Pharmaceuticals Kingdom
GSK Gives up its Patent on Rosiglitazone in China
SFDA to Abolish Lifelong Qualification of Clinical Research Bases
China's First Anti-SARS Drug Approved for Clinical Use
The U.S. Government not to Forbid Price Rise of Abbott Laboratories' Anti-AIDS Drug
Mylan to Acquire King Pharmaceuticals at $4 Billion
The European Stock Markets Closed High; Pharmaceutical Stocks Performed Strongly
Novartis Posted $1.55 Billion Net Profit in the Second Quarter
The Patent to " Viagra " Announced Invalid in China; Price of Domestic " Viagra " to Drop 80%
Roche Agrees to Sell Its OTC Subsidiary to Bayer
The European Stock Markets Stay Flat; High-tech Stocks Go Strong while Medical Stocks Drop
Dissatisfied with China's Patent Verdict, Pfizer Threatens to Reduce Investments in China
Viagra Patent Declared Invalid in China
Shenzhen Nep-Star Obtained $40 Million Investment from Goldman Sachs
Diversified Business Strategy Terminates the Development of Sanjiu Empire
Chinese Drug R&D at Crisis
Inside Story: China Resources' Acquisition of Donge EJiao Initiated the Civil War in Medical Sector
A Win-Win Situation: M&A of DongE Ejiao and China Resources
China Resources Targets the Hematinic Market
The Future of the Chinese Pharmaceutical Market
M&A to Forge Pharmaceutical Giants in China
Off-Patent Drugs Allure Copycats in China
Generics Remains to Dominate the Chinese Drug Market
The Pui's Lost the Lawsuit Against the NDRC : Does the Chinese Drug Pricing Policy Discriminate?
Ministry of Health: Policy for Centralized Drug Procurement to Promulgate
Central Authorities Decides Large-scale Investments for Medical Sector etc.